WallStSmart

Harte Hanks Inc (HHS)vsRTX Corporation (RTX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

RTX Corporation generates 60368% more annual revenue ($93.50B vs $154.63M). RTX leads profitability with a 8.3% profit margin vs -3.7%. HHS appears more attractively valued with a PEG of 1.19. RTX earns a higher WallStSmart Score of 59/100 (C).

HHS

Avoid

33

out of 100

Grade: F

Growth: 2.0Profit: 2.0Value: 4.3Quality: 5.5
Piotroski: 3/9Altman Z: 14.49

RTX

Buy

59

out of 100

Grade: C

Growth: 6.7Profit: 6.0Value: 4.3Quality: 6.0
Piotroski: 6/9Altman Z: 1.58
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

HHSSignificantly Overvalued (-54.3%)

Margin of Safety

-54.3%

Fair Value

$1.86

Current Price

$4.20

$2.34 premium

UndervaluedFair: $1.86Overvalued

Intrinsic value data unavailable for RTX.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

HHS2 strengths · Avg: 9.0/10
Altman Z-ScoreHealth
14.4910/10

Safe zone — low bankruptcy risk

Price/BookValuation
2.0x8/10

Reasonable price relative to book value

RTX3 strengths · Avg: 8.7/10
Market CapQuality
$266.42B10/10

Mega-cap, among the largest globally

EPS GrowthGrowth
28.7%8/10

Earnings expanding 28.7% YoY

Free Cash FlowQuality
$3.59B8/10

Generating 3.6B in free cash flow

Areas to Watch

HHS4 concerns · Avg: 2.8/10
Market CapQuality
$31.61M3/10

Smaller company, higher risk/reward

Debt/EquityHealth
1.573/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-5.2%2/10

ROE of -5.2% — below average capital efficiency

RTX3 concerns · Avg: 4.0/10
PEG RatioValuation
2.304/10

Expensive relative to growth rate

P/E RatioValuation
34.9x4/10

Premium valuation, high expectations priced in

Altman Z-ScoreHealth
1.584/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : HHS

The strongest argument for HHS centers on Altman Z-Score, Price/Book. PEG of 1.19 suggests the stock is reasonably priced for its growth.

Bull Case : RTX

The strongest argument for RTX centers on Market Cap, EPS Growth, Free Cash Flow. Revenue growth of 14.5% demonstrates continued momentum.

Bear Case : HHS

The primary concerns for HHS are Market Cap, Debt/Equity, Piotroski F-Score. Debt-to-equity of 1.57 is elevated, increasing financial risk.

Bear Case : RTX

The primary concerns for RTX are PEG Ratio, P/E Ratio, Altman Z-Score.

Key Dynamics to Monitor

HHS profiles as a turnaround stock while RTX is a value play — different risk/reward profiles.

RTX carries more volatility with a beta of 0.29 — expect wider price swings.

RTX is growing revenue faster at 14.5% — sustainability is the question.

RTX generates stronger free cash flow (3.6B), providing more financial flexibility.

Bottom Line

RTX scores higher overall (59/100 vs 33/100) and 14.5% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Harte Hanks Inc

INDUSTRIALS · CONGLOMERATES · USA

Harte Hanks, Inc. is a customer experience company in the United States and internationally. The company is headquartered in Chelmsford, Massachusetts.

Visit Website →

RTX Corporation

INDUSTRIALS · AEROSPACE & DEFENSE · USA

Raytheon Technologies Corporation is an American multinational aerospace and defense conglomerate headquartered in Waltham, Massachusetts. It is one of the largest aerospace, intelligence services providers, and defense manufacturers in the world by revenue and market capitalization. Raytheon Technologies (RTX) researches, develops, and manufactures advanced technology products in the aerospace and defense industry, including aircraft engines, avionics, aerostructures, cybersecurity, guided missiles, air defense systems, satellites, and drones.

Visit Website →

Want to dig deeper into these stocks?